Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Revenue of Novavax, Inc. (NVAX)
Revenue in 2023 (TTM): $983.71 M
According to Novavax, Inc.'s latest financial reports the company's current revenue (TTM) is $983.71 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Novavax, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $983.71 M | $639.94 M | $-487,390,000 | $-543,031,000 | $-545,062,000 |
| 2022 | $1.6 B | $696.31 M | $-604,713,000 | $-653,647,000 | $-657,939,000 |
| 2021 | $1.15 B | $1.13 B | $-1,680,748,000 | $-1,714,536,000 | $-1,743,751,000 |
| 2020 | $475.6 M | $-271,429,000 | $-398,229,000 | $-418,259,000 | $-427,505,000 |
| 2019 | $18.66 M | $-95,180,000 | $-114,830,000 | $-132,694,000 | $-130,102,000 |
| 2018 | $34.29 M | $34.29 M | $-162,977,000 | $-184,748,000 | $-184,748,000 |
| 2017 | $31.18 M | $31.18 M | $-159,880,000 | $-183,769,000 | $-183,769,000 |
| 2016 | $15.35 M | $-222,586,000 | $-258,496,000 | $-279,966,000 | $-279,966,000 |
| 2015 | $36.25 M | $-126,394,000 | $-150,713,000 | $-156,937,000 | $-156,937,000 |
| 2014 | $30.66 M | $15.67 M | $-78,366,000 | $-82,947,000 | $-82,947,000 |
| 2013 | $20.92 M | $12.69 M | $-49,207,000 | $-51,958,000 | $-51,983,000 |
| 2012 | $22.08 M | $7.38 M | $-26,809,000 | $-28,507,000 | $-28,507,000 |
| 2011 | $14.69 M | $7.69 M | $-17,330,000 | $-18,952,000 | $-19,364,000 |
| 2010 | $343 K | $343 K | $-35,708,000 | $-36,158,000 | $-35,708,000 |
| 2009 | $325 K | $325 K | $-38,374,000 | $-38,374,000 | $-38,374,000 |
| 2008 | $1.06 M | $1.06 M | $-33,746,000 | $-36,049,000 | $-36,049,000 |
| 2007 | $1.51 M | $1.29 M | $-28,590,000 | $-34,765,000 | $-34,765,000 |
| 2006 | $4.68 M | $-1,790,000 | $-18,288,000 | $-23,068,000 | $-23,068,000 |
| 2005 | $7.39 M | $1.6 M | $-5,366,000 | $-11,174,000 | $-11,174,000 |
| 2004 | $8.26 M | $4.77 M | $-21,023,000 | $-25,920,000 | $-25,920,000 |
| 2003 | $11.79 M | $9.73 M | $-14,868,000 | $-17,273,000 | $-17,273,000 |
| 2002 | $15.01 M | $11.45 M | $-20,420,000 | $-22,697,000 | $-22,697,000 |
| 2001 | $24.07 M | $20.01 M | $-5,766,000 | $-9,745,000 | $-9,745,000 |
| 2000 | $2.48 M | $3.07 M | $-12,148,000 | $ | $-12,191,000 |
| 1999 | $1.2 M | $1.6 M | $-4,200,000 | $ | $-4,500,000 |
| 1998 | $700 K | $1000 K | $-4,900,000 | $-4,900,000 | $-4,800,000 |
| 1997 | $500 K | $800 K | $-4,500,000 | $-4,600,000 | $-4,500,000 |
| 1996 | $100 K | $400 K | $-5,200,000 | $-5,400,000 | $-5,500,000 |